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Introduction: To investigate the feasibility and clinical impact of
the 7th edition of the “Tumor, Node, Metastasis” (TNM) classifica-
tion scheme in lung cancer as proposed by the International Asso-
ciation for the Study of Lung Cancer (IASLC) for non-small cell
lung cancer.
Methods: We evaluated the feasibility of the new staging system in
our routine biweekly multidisciplinary lung cancer staging confer-
ence compared with the 6th TNM staging in a prospective manner
from April 2008 to June 2009. The impact of IASLC staging versus
the 6th TNM staging was observed at three levels: change in
substaging, staging, and clinical management (based on the discus-
sion within the staging conference).
Results: From 348 patients discussed during these conferences, 226
eligible non-small cell lung cancer patients newly diagnosed within
the study period were reviewed and clinically staged. The majority
were elderly (median age, 67 years) and men (58%). Of these, 23
patients had different staging, and four patients had different sub-
staging in the IASLC staging compared with the 6th TNM staging.
An impact on clinical management was seen in 2.7% (6 of 226) of
these patients because of coding ipsilateral different-lobe metastasis
as T4 instead of M1.
Conclusions: The new staging system was clinically feasible and
resulted in some (27 of 226, 12%) differences in staging. An impact
on clinical decision making was occasionally seen within our insti-
tutional practice. Further studies are needed to investigate the
comprehensive and long-term impact of the new staging system.
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Lung cancer is a leading cause of cancer mortality aroundthe world, and non-small cell lung cancer (NSCLC) com-
prises the majority of lung cancers. Staging is important for
prognosis and treatment decision making, and some debate
has occurred about the 1997 “tumor, node, metastasis”
(TNM) staging system.1–3
The 7th edition of TNM in lung cancer was published by
the International Union Against Cancer and the American Joint
Committee on Cancer, with changes based primarily on propos-
als from the International Staging Project of the International
Association for the Study of Lung Cancer (IASLC).4,5
This new staging system has been introduced in many
medical journals among different medical specialties.6–9 Part
of the new staging system has also been externally validated
in terms of prognosis in surgical cases of NSCLC or patients
with advanced nonbronchioalveolar carcinoma NSCLC.10–12
Some impact may also be observed in pathologic specimen
processing due to this new staging system.13 However, to our
knowledge, no study related to the clinical implementation,
and impact of the new staging system has been reported.
Thus, the objective of this study was to investigate the
feasibility and clinical impact of this new staging system for
NSCLC in a prospective manner.
PATIENTS AND METHODS
Study Setting
As a major tertiary medical center in central Taiwan
with about 2000 beds, routine multidisciplinary lung cancer
staging conferences have been held in our institute since
2001. All “new” and “treated” patients with lung cancer
recorded by the lung cancer case manager (H.H.W.) are
reviewed in this biweekly meeting. The “treated” patients list
consisted of those patients whose treatment decision making
had largely been made. The “new” patients list consisted of
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those patients whose main treatment had not yet been de-
cided. Generally, the “new” list reflected those diagnosed
shortly before the date of the meeting, and the “treated” list
reflected those diagnosed shortly after the date of previous
meeting. Since April 2008, the feasibility and impact of the
new staging system for “new” lung cancer patients were
evaluated in a prospective manner in addition to the 6th TNM
classification, and feasibility was evaluated based on whether
consensus on IASLC staging could be achieved in this meet-
ing. The data we collected and report in this study were the
result of our routine records of lung cancer team meeting
discussions, which were conducted by department/team head
(T.-C.H.).
Data Collected
Demographic (gender and age), tumor (primary site and
histology), and patient characteristics (Eastern Cooperative
Oncology Group performance status) were collected. Histol-
ogy was categorized as adenocarcinoma, squamous cell car-
cinoma, or other. Both 6th TNM and IASLC staging were
based on discussion within this meeting, as was suggested
treatment. Treatment was categorized as operation or not,
systemic anticancer treatment or not, and radiotherapy or not.
The staging workup was categorized into (A) conventional
(primarily chest computed tomography based), (B) positron
emission tomography included, or (C) cytopathological ex-
amination other than primary sites, which was primarily
decided by the treating physician. The impact of IASLC
staging in addition to the 6th TNM staging was observed at
three levels: change in substaging (such as from IIA to IIB),
change in staging (such as from III to IV), or change in
clinical management, which was based on discussions within
this conference.
Statistical Analysis
The results were tabulated and described by descriptive
analyses. The 2 test was used for comparisons among
different groups. All analyses were done using the Statistical
Analysis Software system for Windows, version 9.00 (Statis-
tical Analysis Software Institute, Cary, NC).
RESULTS
Patients
Between April 2008 and June 2009, 537 newly diag-
nosed patients with lung cancer were added, according to
institutional cancer registry, including 462 patients with his-
tology-proven NSCLC. During the same period, 348 patient-
visits were discussed as “new” patients for further decision
making in our biweekly meetings, where “patient-visits”
indicates that one patient might be discussed several time
over the disease course. Among these “new” patient-visits
reviewed and clinically staged in these conference (n  348),
those with no tissue diagnosis yet (n  66), histology other
than NSCLC (n  24), history of previous treatment (n 
12), further workup needed (n 15), and double cancer (n
5) were excluded from our analysis. These exclusion criteria
were decided during the first month (April 2008) when we
began the study. The remaining 226 newly diagnosed patients
with NSCLC constituted our study population (Table 1).
Consensus for both 6th TNM and IASLC staging was
achieved for these 226 patients at these meetings. Most of
these patients were elderly males with adenocarcinomas.
Staging Results
The staging workups were 133 (59%), 50 (22%), and
43 (19%) for workups A, B, and C, respectively. The stage
distribution was 14, 8, 56, and 148 for stages I, II, III, and IV,
respectively, by the 6th TNM staging. The corresponding
numbers were 12, 9, 53, and 152 by the new staging system
(Table 2). In total, 23 patients had different staging, and four
patients had different substaging using IASLC versus the 6th
TNM staging. The reasons for these changes in staging and
substaging are shown in Table 3. The predominant reasons
for these differences (11 of 27, 41%) were due to coding of
malignant effusion as M1 instead of T4, followed by coding
of ipsilateral different-lobe nodules as T4 instead of M1 (7 of
27, 26%). Operations were indicated for 38 patients, whereas
systemic treatment and radiotherapy were suggested for 156
TABLE 1. Characteristics of the Study Group (n  226)
Characteristics No. Percentagea
Age (yr) Median: 67 Range: 33–87
Gender
Male 132 58
Female 94 42
Primary site
RUL 53 23
RML 13 6
RLL 42 19
LUL 33 15
LLL 49 22
NA 36 16
Histology
Adenocarcinoma 144 64
SCC 54 24
Others 28 12
PS
0–2 184 81
3–4 38 17
Missing 4 2
a Rounded.
LLL, left lower lobe; LUL, left upper lobe; NA, not applicable; PS, performance
status; RML, right middle lobe; RLL, right lower lobe; RUL, right upper lobe; SCC,
squamous cell carcinoma.
TABLE 2. Staging Distribution for 6th TNM versus IASLC
(n  226)
Stage I,
No. (%)a
Stage II,
No. (%)a
Stage III,
No. (%)a
Stage IV,
No. (%)a
6th TNM 14 (6) 8 (4) 56 (25) 148 (65)
IASLC 12 (5) 9 (4) 53 (23) 152 (67)
a Rounded.
IASLC, International Association for the Study of Lung Cancer; TNM, tumor,
node, metastasis.
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and 47 patients, respectively. An impact in clinical manage-
ment was seen in 2.7% (6 of 226) of these patients, including
a consideration of operation and radical thoracic radiotherapy
for three patients each, in addition to chemotherapy alone. All
were due to coding an ipsilateral different-lobe metastasis as
T4 instead of M1. The number (percentage) of patients with
differences in staging or substaging was 10 (8%), eight
(16%), and nine (21%) for work-up methods A, B, and C,
respectively (p  0.038). Use of an advanced staging proce-
dure (work-up B or C) was associated with changes between
6th TNM staging and IASLC staging/substaging (17 of 93
versus 10 of 133; p  0.014).
DISCUSSION
The long-awaited new staging system for lung cancer
has finally been published.5 Our study revealed that adoption
of the 7th TNM staging of lung cancer, as proposed by
IASLC, was feasible for newly diagnosed NSCLC in our
routine multidisciplinary lung cancer staging conferences.
The objectives of the staging system are to aid clini-
cians and investigators in planning treatment, assessing prog-
nosis stratification, and facilitating communication.14 There is
no doubt that the new staging system, as proposed by IASLC,
is a major advance, as revealed by the superior prognostic
stratification.4 This achievement was validated by retrospec-
tive studies10–12 and was further supported by this study
evaluating its clinical feasibility and potential clinical impact.
In our study, this clinical impact was seen primarily in
patients with ipsilateral different-lobe nodules. Although the
justification that we proposed to treat selected patients with
ipsilateral different-lobe nodules aggressively as stage III,
instead of stage IV, patients deserve further prospective
studies; this concept was compatible with the present Na-
tional Comprehensive Cancer Network guidelines.15
Although this new staging system may also be applied
to small-cell lung cancer,16 it was originally based on a
database of patients with NSCLC only.4 Thus, only patients
with NSCLC were included in our study.
This study has some limitations. First, not all newly
diagnosed patients with lung cancer during the study period
were included in our analysis; in particular, some early-stage
patients might not be included due to the unavailability of a
tissue diagnosis before operation. This was also the number
one cause (n  66) of exclusion from our study. Thus, the
impact of the new staging system on early-stage NSCLC
might not be fully captured by our study. However, because
changes in staging primarily occurred in IASLC stages II
to IV patients,4 underrepresentation of patients with early-
stage NSCLC in our study population might not lead to any
significant change in staging result or clinical impact.
Additionally, only “new” patients, and not “treated” patients,
were included in our study. However, because these two
groups only reflected patients diagnosed at times before and
after the routine meetings, the omission of “treated” patients
should only lead to a reduction in sample size not to limited
representation.
Second, our study population was not staged uniformly.
However, this made our results more relevant to the real
world, where wide variations exist in the pattern of care for
staging procedures of lung cancer.1,17 As suggested by the
American College of Chest Physicians,18 tissue biopsies for
abnormalities are preferred for accurate staging, and positron
emission tomography has better sensitivity and specificity
than does computed tomography. Thus, staging workups
were categorized in three levels in our study. Our results also
revealed that the impact of the new staging system might be
enhanced if the use of the advanced staging procedures is
increased. On the other hand, our results also indicated that
conventional investigation alone (work-up group A) might
often be sufficient for staging, especially for a predominantly
advanced disease patient population.
Another limitation of our study is the moderate sample
size, based on data from a single institution. However, for the
seven situations where T or M coding was different between
the 6th TNM and IASLC staging,4 all seven happened in our
study group (Table 3). Thus, we believe our study population
was big enough to be representative for a single institution.
However, multinational and multiinstitutional experiences
are needed for further evaluation of the comprehensive im-
pact of the new staging system, though we believe our
findings provide a good starting point.
The lung cancer staging system may be further im-
proved in the future. N staging was not revised in this new
staging system, although some subclassification has been
suggested.19 Other nonanatomic prognostic factors may also
be incorporated in the future.14,20 Currently, a prospective
project is underway by IASLC.21
In conclusion, the new staging system was clinically
feasible and led to some (27 of 226, 12%) differences in
staging. Most of the changes were due to coding of malignant
effusion as M1 instead of T4. An impact on clinical decision
making was occasionally seen (6 of 226, 2.7%) within our
institutional practice. Further studies are needed to investi-
gate the comprehensive and long-term impact of the new
staging system.
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TABLE 3. Reasons for Change in Stage and Substage
(n  27)
Sixth Edition
T/M Descriptor
IASLC
T/M
Sixth Edition
T/M Staging
IASLC
Staging
Case No.
(%)a
T2 (5 cm) T2a IIb IIa 1 (4)
T2 (5–7 cm) T2b Ib IIa 2 (7)
T2 (7 cm) T3 IIb IIIa 2 (7)
T4 (Same lobe) T3 IIIb IIb 1 (4)
T4 (Same lobe) T3 IIIb IIIa 2 (7)
T4 (Extension) T4 IIIb IIIa 1 (4)
M1 (Ipsilateral lung) T4 IV IIIa 5 (19)
M1 (Ipsilateral lung) T4 IV IIIb 2 (7)
T4 (Pleural effusion) M1a IIIb IV 11 (41)
a Rounded.
IASLC, International Association for the Study of Lung Cancer.
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